Edition:
India

Sosei Group regains worldwide rights from Teva to develop and commercialize novel small molecule CGRP antagonists for migraine and other severe headaches


Tuesday, 13 Mar 2018 

March 13 (Reuters) - Sosei Group Corp <4565.T>:Says co has regained worldwide rights from Teva Pharmaceutical Industries Ltd., to develop and commercialize lead candidate HTL0022562 and other novel small molecule CGRP antagonists for the treatment of migraine and other severe headaches. 

Company Quote

2438.0
-34.0 -1.38%
11:30am IST